BioNexus Gene Lab Corp (BGLC) Stock Statistics & Valuation Metrics

BioNexus Gene Lab Corp has a market cap or net worth of $4.47M. The enterprise value is $1.32M.

BioNexus Gene Lab Corp has 2,933,442 shares outstanding. The number of shares has decreased by -2.65% in one year.

BioNexus Gene Lab Corp’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -35.93%.

The current PE Ratio of BioNexus Gene Lab Corp is ―. BioNexus Gene Lab Corp’s PEG ratio is -0.03.

In the last 12 months, BioNexus Gene Lab Corp had revenue of 7.42M and earned -2.98M in profits. Earnings per share was -1.61.

In the last 12 months, operating cash flow was -842.37K and capital expenditures -28.05K, giving a free cash flow of -870.42K billion.

BioNexus Gene Lab Corp pays an annual dividend of ―, resulting in a dividend yield of ―

BioNexus Gene Lab Corp upcoming earnings date is ―, ―.

BioNexus Gene Lab Corp as a current ratio of 10.46, with Debt / Equity ratio of 2.55%

In the past 12 months, BioNexus Gene Lab Corp has paid 0.00 in taxes.

BioNexus Gene Lab Corp EV to EBITDA ratio is -1.83, with an EV/FCF ratio of -2.73.

BioNexus Gene Lab Corp has $3.52M in cash and marketable securities with $198.59K in debt, giving a net cash position of $3.32M billion.

Gross margin is 11.64%, with operating margin of -42.54%, and net profit margin of -40.20%.

The average price target for BioNexus Gene Lab Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―